Anterogen.Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of stem cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn's fistula; Queencell, a stromal vascular fraction used for the regeneration of subcutaneous adipose tissue; and Remodulin injection, a medicine for the treatment of pulmonary arterial hypertension. It also provides cosmetics, such as hair care products comprising SCM2 and SCM2-Black; and skin care products, such as Therastem-Derma, Therastem-White Silk, and Therastem-White Glutathione, as well as human stem cell conditioned media, a cosmetic raw material. In addition, the company offers cell banking services; and analysis services that include sample analysis for clinical studies, as well as conducts biopharmaceutical tests for identification, purity, potency, adventitious virus, etc. Anterogen.Co.,Ltd. was founded in 2000 and is headquartered in Seoul, South Korea.
The current price of 065660.KQ is ₩55,600 KRW — it has increased by +29.91% in the past 24 hours. Watch AnterogenLtd stock price performance more closely on the chart.
What is AnterogenLtd stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange AnterogenLtd stocks are traded under the ticker 065660.KQ.
What is AnterogenLtd market cap?▼
Today AnterogenLtd has the market capitalization of 556.33B
What were AnterogenLtd earnings last quarter?▼
065660.KQ earnings for the last quarter are 217.44 KRW per share, whereas the estimation was N/A KRW resulting in a N/A surprise. The estimated earnings for the next quarter are N/A KRW per share.
What is AnterogenLtd revenue for the last year?▼
AnterogenLtd revenue for the last year amounts to 13.87B KRW.
What is AnterogenLtd net income for the last year?▼
065660.KQ net income for the last year is -4.59B KRW.